The Federal Trade Commission Thursday said Doan's pills are no better at relieving back pain than competing analgesics and will seek an order barring maker Ciba-Geigy from making superiority claims for Doan's. The FTC said there was no support for the suggested claim that an exclusive ingredient in Doan's made the product better for back aches. Ciba-Geigy denied the charges and said it would fight the case. The FTC said it may also seek corrective advertising during the administrative hearing that will now follow. Current agency Jordan, McGrath, Case & Taylor, New York, did reach a consent agreement, promising to have at least two clinical studies before making claims for Doan's or other over-the-counter drugs.